The introduction of teplizumab (Tzield®) marks a pivotal development in the therapeutic approach to presymptomatic type 1 diabetes (T1D).
A groundbreaking study from Cincinnati Children’s reveals that hospitalized kids with Type 1 diabetes can safely continue using their home insulin pumps—challenging long‑standing clinical protocols. The findings could reshape pediatric inpatient care nationwide.
Research from Cincinnati Children’s shows home insulin pumps can be safely used in hospitalized kids, reducing hyperglycemia and supporting family‑managed diabetes care.
AI-powered eye exams at Cincinnati Children’s boost diabetic retinopathy screening rates in kids—from 50% to over 90%—without extra appointments.
Our health system is transforming pediatric diabetes care with real-time dashboards that close gaps in technology access and improve clinical outcomes.
Cincinnati Children’s Mobile Care Center brings pediatric endocrinology services closer to home, improving access to diabetes and endocrine care for families.